AB0450 Effect of adalimumab discontinuation on patient-reported outcomes and work productivity in early rheumatoid arthritis patients who achieved low disease activity following 26 weeks of treatment: Data from the optima study

Abstract

BackgroundIncreasing attention has been focused on patient-reported outcomes (PROs) and work productivity as important outcomes in RA. In the Optimal Protocol for Treatment Initiation with Methotrexate (MTX) and Adalimumab (ADA)...